Developer docs
API playgroundTry for free, no card

Search company profiles

Artemetrx

Full company profile

uuid0008466

Namestring
Artemetrx
Legal namestring
Pharmaceutical Strategies Group, LLC
Websiteurl
artemetrx.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Artemetrx is a web-based integrated analytics platform that transforms pharmacy and medical claims data into actionable intelligence for drug spend management. Built on more than 30 years of pharmacy benefit management expertise from its parent Pharmaceutical Strategies Group (PSG), the platform integrates pharmacy and medical claims at the individual patient level, processing approximately 1.5 billion combined claims across 22 million pharmacy lives. It operates as a product line of PSG, which was acquired by EPIC Insurance Brokers in 2023.

The platform comprises multiple specialized modules: Core for foundational spend and trend analytics; Diagnostic for issue identification; Extend for custom reporting; GeneCQ for gene therapy risk mitigation; SpecialtyCQ for specialty drug analytics; Pricing Monitor for PBM pricing guarantee compliance; Rebate Monitor for rebate contract adherence; and Plus for hands-on support services. The underlying clinical rules engine evaluates over 1,000 unique parameters including first-line therapy and diagnosis codes to identify unnecessary medication spend and fraud, waste, and abuse patterns. The platform also performs anomaly detection to flag unusual utilization patterns, such as detecting a 400% utilization spike for the specialty drug Miebo.

Artemetrx serves enterprise healthcare payers across four primary segments: health plans, employers, health systems, and labor unions. Revenue is generated through SaaS subscription and licensing fees, delivered as part of PSG's broader pharmacy consulting engagements via direct enterprise field sales. The company does not publicly disclose pricing and operates without dedicated mobile applications or public APIs, indicating a tightly coupled, consulting-led commercial model rather than a self-serve product motion.

Short descriptiontext

Artemetrx is a web-based analytics platform that integrates pharmacy and medical claims data to manage drug spend for health plans, employers, health systems, and labor unions, operated by Pharmaceutical Strategies Group, an EPIC Insurance Brokers subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPlano, United States
HQ citystring
Plano
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacy benefit analytics, drug spend management, PBM contract auditing, specialty drug analytics, pharmacy claims analytics
Industry2 codes
PRIMARYHLAEAKAK
Pharmacy Benefit Analytics, Reporting & Employer Consulting
SECONDARYHLAEAKAL
PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools)
NAICS code1 code
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Pharmacy Benefits Analytics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Analytics Platform Subscription
TypeSubscription Recurring
Description

Artemetrx is a web-based SaaS platform that provides reports, dashboards, and analytical tools for managing drug spend and trend. Revenue appears to be generated through subscription/licensing fees as part of PSG's broader consulting service offerings.

psgconsults.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1Artemetrx Core
Description

Integrated data platform for managing spend and trend with unified pharmacy and medical data.

psgconsults.com
+7 more records
Core offering1 text field

Artemetrx is an integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for managing drug spend and trend across both pharmacy and medical benefits. Built on more than 30 years of drug management expertise, the platform provides reports, dashboards, and analytical tools covering 1.5 billion claims across 22 million pharmacy lives, serving payers and benefit sponsors through PSG's consulting organization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 2.5% decrease in PMPM gross cost and $11M in savings for one large health plan
+6 more records
Product overview1 text field

Artemetrx is an integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for drug spend and trend management. The platform operates as a core system with multiple specialized modules: Core provides foundational spend and trend analytics; Diagnostic enables issue identification; Extend offers custom reporting; GeneCQ addresses gene therapy risk; Plus provides hands-on support; Pricing Monitor tracks PBM pricing guarantees; Rebate Monitor monitors rebate contract compliance; and SpecialtyCQ focuses on specialty drug analytics. Built on more than 30 years of drug management expertise, the platform covers both pharmacy and medical benefits and integrates data at the individual patient level.

Product and service9 records
1Artemetrx Analytics Platform
CategoryPharmacy Benefits Analytics
Description

Integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for managing drug spend and trend across both pharmacy and medical benefits, serving payers and benefit sponsors.

2Artemetrx Core
CategoryPharmacy Benefits Analytics
Description

Core analytics foundation providing standard reports, dashboards, and benchmarking across pharmacy and medical benefits for benefit sponsors.

3Artemetrx Plus
CategoryPharmacy Benefits Analytics
Description

Extended analytics module offering expanded reporting and insights layered on top of the Artemetrx Core platform.

4Artemetrx Diagnostic
CategoryPharmacy Benefits Analytics
Description

Diagnostic-focused analytics module that uncovers clinical and financial opportunities within an organization's drug spend profile.

5Artemetrx Extend
CategoryPharmacy Benefits Analytics
Description

Extension analytics module offering additional reporting and dashboard capabilities for deeper pharmacy and medical benefit analysis.

6Artemetrx Rebate Monitor
CategoryPharmacy Contract Auditing
Description

Standalone analytics product that audits PBM rebate performance and verifies contracted pricing terms to ensure rebate accuracy.

7Artemetrx Pricing Monitor
CategoryPharmacy Contract Auditing
Description

Standalone pricing analytics module that monitors PBM pricing performance and identifies contract compliance gaps.

8Artemetrx SpecialtyCQ
CategorySpecialty Drug Analytics
Description

Specialty drug analytics module focused on managing specialty drug costs, trend, and utilization as a stand-alone solution for benefit sponsors.

9Artemetrx GeneCQ
CategoryGene Therapy Risk Mitigation
Description

Gene therapy risk mitigation solution that identifies and manages gene therapy exposure and catastrophic financial risk within a benefits population.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Artemetrx is a product of Pharmaceutical Strategies Group (PSG), which is an EPIC company. EPIC is a national insurance brokerage that acquired PSG, integrating Artemetrx analytics capabilities into EPIC's benefits consulting offerings for clients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

SmithRx is a technology-led PBM offering transparent pricing and integrated analytics for self-funded employers, representing an emerging competitor that combines PBM administration with embedded data analytics similar to Artemetrx.

TypeDirect peer
Description

EmpiRx Health is a PBM that combines a clinically-driven model with pharmacy analytics and population health management, competing closely with Artemetrx's specialty drug and clinical optimization modules.

TypeDirect peer
Description

Truveris is a healthcare technology company providing PBM contract management, pharmacy benefit analytics, and audit services to employers, health plans, and labor unions — directly overlapping with Artemetrx's analytics and PBM oversight offerings.

TypeBroad incumbent
Description

Express Scripts is a top-three PBM (part of Cigna/Evernorth) that provides PBM services, clinical programs, and reporting to payers and employers — a broad incumbent whose internal analytics compete with third-party platforms like Artemetrx.

TypeBroad incumbent
Description

CVS Caremark is one of the largest US PBMs (part of CVS Health) offering integrated PBM, specialty pharmacy, and analytics services — a broad incumbent whose captive offerings compete with Artemetrx.

TypeBroad incumbent
Description

Navitus is a full-service PBM with transparent pricing and clinical management offerings for health plans, employers, and government programs, providing comparable analytics-adjacent PBM services to Artemetrx's customer base.

7RxBenefits
TypeDirect peer
Description

RxBenefits provides PBM procurement, contract oversight, and clinical analytics for self-funded employers and labor unions, mirroring Artemetrx's employer-focused PBM analytics and consulting model.

TypeBroad incumbent
Description

MedImpact is an independent PBM with clinical programs and analytics capabilities serving health plans, employers, and government programs — a broader incumbent that competes with Artemetrx in PBM analytics and audit.

9Confidio
TypeDirect peer
Description

Confidio is a pharmacy benefits consulting firm offering PBM procurement, benchmarking, and ongoing analytics oversight for employers and health plans, directly comparable to Artemetrx's consulting-enabled analytics approach.

TypeBroad incumbent
Description

OptumRx is the largest US PBM (part of UnitedHealth Group) and increasingly offers proprietary analytics and audit tools bundled with PBM administration, making it a broad incumbent competitor in employer-side PBM analytics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Artemetrx

Pharmacy Benefits Analyticsartemetrx.com

Artemetrx is a web-based analytics platform that integrates pharmacy and medical claims data to manage drug spend for health plans, employers, health systems, and labor unions, operated by Pharmaceutical Strategies Group, an EPIC Insurance Brokers subsidiary.

What Artemetrx does

Artemetrx is a web-based integrated analytics platform that transforms pharmacy and medical claims data into actionable intelligence for drug spend management. Built on more than 30 years of pharmacy benefit management expertise from its parent Pharmaceutical Strategies Group (PSG), the platform integrates pharmacy and medical claims at the individual patient level, processing approximately 1.5 billion combined claims across 22 million pharmacy lives. It operates as a product line of PSG, which was acquired by EPIC Insurance Brokers in 2023.

The platform comprises multiple specialized modules: Core for foundational spend and trend analytics; Diagnostic for issue identification; Extend for custom reporting; GeneCQ for gene therapy risk mitigation; SpecialtyCQ for specialty drug analytics; Pricing Monitor for PBM pricing guarantee compliance; Rebate Monitor for rebate contract adherence; and Plus for hands-on support services. The underlying clinical rules engine evaluates over 1,000 unique parameters including first-line therapy and diagnosis codes to identify unnecessary medication spend and fraud, waste, and abuse patterns. The platform also performs anomaly detection to flag unusual utilization patterns, such as detecting a 400% utilization spike for the specialty drug Miebo.

Artemetrx serves enterprise healthcare payers across four primary segments: health plans, employers, health systems, and labor unions. Revenue is generated through SaaS subscription and licensing fees, delivered as part of PSG's broader pharmacy consulting engagements via direct enterprise field sales. The company does not publicly disclose pricing and operates without dedicated mobile applications or public APIs, indicating a tightly coupled, consulting-led commercial model rather than a self-serve product motion.

Artemetrx firmographics

Firmographics
Name
Artemetrx
Legal name
Pharmaceutical Strategies Group, LLC
Website
https://artemetrx.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
1–10 employees
Short description
Artemetrx is a web-based analytics platform that integrates pharmacy and medical claims data to manage drug spend for health plans, employers, health systems, and labor unions, operated by Pharmaceutical Strategies Group, an EPIC Insurance Brokers subsidiary.
Ownership category
akta.pro rank

Artemetrx industry classification

Industry
Product category
Pharmacy Benefits Analytics
NAICS
Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAEAKAK
Pharmacy Benefit Analytics, Reporting & Employer Consulting
SECONDARYHLAEAKAL
PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools)

Keywords

  • Pharmacy benefit analytics
  • Drug spend management
  • PBM contract auditing
  • Specialty drug analytics
  • Pharmacy claims analytics

Where Artemetrx is headquartered

Location

Headquarters

HQ city
Plano
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Artemetrx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Analytics Platform Subscription: Artemetrx is a web-based SaaS platform that provides reports, dashboards, and analytical tools for managing drug spend and trend. Revenue appears to be generated through subscription/licensing fees as part of PSG's broader consulting service offerings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Artemetrx product offering

Product offering

Core offering

Artemetrx is an integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for managing drug spend and trend across both pharmacy and medical benefits. Built on more than 30 years of drug management expertise, the platform provides reports, dashboards, and analytical tools covering 1.5 billion claims across 22 million pharmacy lives, serving payers and benefit sponsors through PSG's consulting organization.

Product overview

Artemetrx is an integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for drug spend and trend management. The platform operates as a core system with multiple specialized modules: Core provides foundational spend and trend analytics; Diagnostic enables issue identification; Extend offers custom reporting; GeneCQ addresses gene therapy risk; Plus provides hands-on support; Pricing Monitor tracks PBM pricing guarantees; Rebate Monitor monitors rebate contract compliance; and SpecialtyCQ focuses on specialty drug analytics. Built on more than 30 years of drug management expertise, the platform covers both pharmacy and medical benefits and integrates data at the individual patient level.

Differentiator

Problem solved

Functional benefit

Brands

  • Artemetrx Core: Integrated data platform for managing spend and trend with unified pharmacy and medical data.
  • Artemetrx Diagnostic
  • Artemetrx Extend
  • GeneCQ
  • Artemetrx Plus
  • Pricing Monitor
  • Rebate Monitor
  • SpecialtyCQ

Products and services

  • Artemetrx Analytics Platform Integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for managing drug spend and trend across both pharmacy and medical benefits, serving payers and benefit sponsors.
  • Artemetrx Core Core analytics foundation providing standard reports, dashboards, and benchmarking across pharmacy and medical benefits for benefit sponsors.
  • Artemetrx Plus Extended analytics module offering expanded reporting and insights layered on top of the Artemetrx Core platform.
  • Artemetrx Diagnostic Diagnostic-focused analytics module that uncovers clinical and financial opportunities within an organization's drug spend profile.
  • Artemetrx Extend Extension analytics module offering additional reporting and dashboard capabilities for deeper pharmacy and medical benefit analysis.
  • Artemetrx Rebate Monitor Standalone analytics product that audits PBM rebate performance and verifies contracted pricing terms to ensure rebate accuracy.
  • Artemetrx Pricing Monitor Standalone pricing analytics module that monitors PBM pricing performance and identifies contract compliance gaps.
  • Artemetrx SpecialtyCQ Specialty drug analytics module focused on managing specialty drug costs, trend, and utilization as a stand-alone solution for benefit sponsors.
  • Artemetrx GeneCQ Gene therapy risk mitigation solution that identifies and manages gene therapy exposure and catastrophic financial risk within a benefits population.

Quantifiable outcome

  • 2.5% decrease in PMPM gross cost and $11M in savings for one large health plan
  • +6 more outcomes

Companies that use Artemetrx

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Artemetrx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Artemetrx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • EPIC (Insurance Brokerage)coreStrategic or Co-development PartnerArtemetrx is a product of Pharmaceutical Strategies Group (PSG), which is an EPIC company. EPIC is a national insurance brokerage that acquired PSG, integrating Artemetrx analytics capabilities into EPIC's benefits consulting offerings for clients.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Artemetrx competitors and assessment

Company assessment

Emerging players

  • SmithRx: SmithRx is a technology-led PBM offering transparent pricing and integrated analytics for self-funded employers, representing an emerging competitor that combines PBM administration with embedded data analytics similar to Artemetrx.

Direct peers

  • EmpiRx Health: EmpiRx Health is a PBM that combines a clinically-driven model with pharmacy analytics and population health management, competing closely with Artemetrx's specialty drug and clinical optimization modules.
  • Truveris: Truveris is a healthcare technology company providing PBM contract management, pharmacy benefit analytics, and audit services to employers, health plans, and labor unions — directly overlapping with Artemetrx's analytics and PBM oversight offerings.
  • RxBenefits: RxBenefits provides PBM procurement, contract oversight, and clinical analytics for self-funded employers and labor unions, mirroring Artemetrx's employer-focused PBM analytics and consulting model.
  • Confidio: Confidio is a pharmacy benefits consulting firm offering PBM procurement, benchmarking, and ongoing analytics oversight for employers and health plans, directly comparable to Artemetrx's consulting-enabled analytics approach.

Broad incumbents

  • Express Scripts: Express Scripts is a top-three PBM (part of Cigna/Evernorth) that provides PBM services, clinical programs, and reporting to payers and employers — a broad incumbent whose internal analytics compete with third-party platforms like Artemetrx.
  • CVS Caremark: CVS Caremark is one of the largest US PBMs (part of CVS Health) offering integrated PBM, specialty pharmacy, and analytics services — a broad incumbent whose captive offerings compete with Artemetrx.
  • Navitus Health Solutions: Navitus is a full-service PBM with transparent pricing and clinical management offerings for health plans, employers, and government programs, providing comparable analytics-adjacent PBM services to Artemetrx's customer base.
  • MedImpact Healthcare Systems: MedImpact is an independent PBM with clinical programs and analytics capabilities serving health plans, employers, and government programs — a broader incumbent that competes with Artemetrx in PBM analytics and audit.
  • OptumRx: OptumRx is the largest US PBM (part of UnitedHealth Group) and increasingly offers proprietary analytics and audit tools bundled with PBM administration, making it a broad incumbent competitor in employer-side PBM analytics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Artemetrx social profiles

Digital presence

Artemetrx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Artemetrx leadership team

Management profile

Number of profiles

Profiles1 record

Artemetrx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Artemetrx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artemetrx

What does Artemetrx do?

Artemetrx is an integrated web-based analytics platform that transforms pharmacy and medical claims data into actionable intelligence for managing drug spend and trend across both pharmacy and medical benefits. Built on more than 30 years of drug management expertise, the platform provides reports, dashboards, and analytical tools covering 1.5 billion claims across 22 million pharmacy lives, serving payers and benefit sponsors through PSG's consulting organization.

Is Artemetrx a public or private company?

Artemetrx is a private company. It is classified as corporate owned and is currently operating.

When was Artemetrx founded?

Artemetrx was founded in 1999. It employs 1 to 10 people.

Where is Artemetrx based?

Artemetrx is headquartered in Plano, United States, in the North America region.

How does Artemetrx make money?

One revenue line is on record: analytics Platform Subscription.

Who are Artemetrx's main competitors?

SmithRx is listed as an emerging player. Direct peers are EmpiRx Health, Truveris, RxBenefits and Confidio. Broad incumbents are Express Scripts, CVS Caremark, Navitus Health Solutions, MedImpact Healthcare Systems and OptumRx.

Does Artemetrx have an API?

No public API is recorded for Artemetrx.

What industry is Artemetrx in?

Artemetrx's product category is Pharmacy Benefits Analytics. Its primary akta.pro industry code is HLAEAKAK, Pharmacy Benefit Analytics, Reporting & Employer Consulting, with a secondary code of HLAEAKAL, PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools). Its NAICS code is 524292 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenefitsProRising costs, greater utilization drive increase in 2022 specialty drug spendSpecialty drug spend continued to increase last year, according to the latest Artemetrx State of Specialty Spend and Trend report. The report cites rising costs and greater utilization as drivers. No specific figures or additional details are provided.PR NewswirePrime Therapeutics launches Specialty Monitor™ to deliver total drug management insightsPrime Therapeutics LLC, a pharmacy benefit manager serving 23 Blue Cross and Blue Shield plans, launched Specialty Monitor™ powered by Artemetrx, a first-of-its-kind integrated data solution combining medical and pharmacy benefits data to manage specialty drug costs. Specialty drugs are projected to represent 60 percent of Prime's total drug expenses by 2021, with the initial rollout reaching 10 health plans covering nearly 10 million members with combined annual specialty drug costs of approximately $7 billion. The tool has already identified savings opportunities, including a $1 million case of duplicate high-cost therapy for hereditary angioedema treatment, with potential to generate hundreds of millions of dollars in savings.PR NewswireArtemetrx Recognized as One of the Most Promising Data Analytics Solutions ProvidersArtemetrx, a provider of advanced analytics and specialty drug cost-management solutions, was named one of the 20 Most Promising Data Analytics Solutions Providers by CIOReview for 2017. The platform, which identified approximately $800 million in savings opportunities for clients in 2016, transforms data into intelligence to improve management of drug spend across pharmacy and medical benefits. Artemetrx is a subsidiary of Pharmaceutical Strategies Group (PSG), a pharmacy intelligence and technology company based in Plano, Texas.GlobeNewswireArtemetrx and Healthcare Bluebook Offer the First Medical Specialty Drug Pricing ToolArtemetrx and Healthcare Bluebook launched ShopSmart Specialty, a pricing comparison tool for medical specialty drugs. The tool highlights pricing variation up to 10-fold, with Remicade ranging from $3,200 to $28,000 monthly, and estimates employers can save up to 13%.GlobeNewswireArtemetrx Announces Release of Specialty Drug Medical SolutionsArtemetrx announced its Specialty Medical Solutions for specialty drugs under the medical benefit, targeting employers and health plans. The company claims plan sponsors can save 30% or more through active management, and notes specialty drug spend will surpass traditional spend in five years.GlobeNewswireArtemetrx Releases a Specialty Drug Trend StudyArtemetrx released its 2013 Specialty Drug Trend Study, projecting specialty drug spend will surpass traditional drug spend by 2018 for commercial plan sponsors. The study found specialty drugs represent 30% of total drug spend, up from 15-20%, and forecasted growth from $290 to $845 per member per year.